Routine poison pill renewal with no market-moving implications. Monitor for any future 13D filings or takeover speculation that would activate the rights. No trading action warranted on this filing alone.
Price Chart
Executive Summary
Neuphoria Therapeutics extended the expiration date of its shareholder rights plan (poison pill) by one year, from October 27, 2026 to October 27, 2027. This is a routine administrative renewal of an existing anti-takeover defense with no material financial impact or change to shareholder economics.
Key Facts
- Board approved Amendment No. 1 to the Rights Agreement on October 23, 2026
- Final Expiration Date extended from October 27, 2026 to October 27, 2027
- Rights remain redeemable as of the filing date
- No changes to exercise price, trigger thresholds, or other economic terms of the rights
- Computershare Trust Company, N.A. remains the Rights Agent
Financial Impact
No financial impact — routine extension of existing rights plan with no change to economic terms
Risk Factors
- Extended rights plan could deter potential acquirers, limiting premium takeout scenarios
- If a hostile bid emerges before October 2027, the pill may trigger significant dilution for the acquirer
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-111863 |
| Document: ea030914601ex4-2.htm | 0001213900-26-111863 |
| Document: 0001213900-26-111863-index-headers.html | 0001213900-26-111863 |
| Document: 0001213900-26-111863-index.html | 0001213900-26-111863 |
| Document: 0001213900-26-111863.txt | 0001213900-26-111863 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $3.44 | awaiting T+60 | — | $3.38 (−1.74%) |
Oct 5, 2026 22d ago | SC 13G | $3.45 | awaiting T+60 | — | $3.38 (−2.03%) |
Sep 18, 2026 5w ago | DEFA14A | $3.71 | awaiting T+60 | — | $3.38 (−8.89%) |
Sep 18, 2026 5w ago | DEFA14A | $3.71 | awaiting T+60 | — | $3.38 (−8.89%) |
Sep 18, 2026 5w ago | DEF 14A | $3.71 | awaiting T+60 | — | $3.38 (−8.89%) |
Jun 26, 2026 17w ago | Press Release | $4.40 $3.74 | ▼ −15.11% | ▼ −19.50% | $3.38 (−23.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers